Stifel initiated coverage on COMPASS Pathways with a new price target
$CMPS
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | $11.00 → $6.00 | Outperform → In-line | Evercore ISI |
| 2/27/2025 | $11.00 | Buy | Stifel |
| 7/23/2024 | $23.00 | Outperform | RBC Capital Mkts |
| 4/1/2024 | $30.00 | Overweight | Morgan Stanley |
| 12/12/2023 | $16.00 | Buy | Deutsche Bank |
| 11/21/2022 | $33.00 | Buy | Berenberg |
| 11/1/2022 | $34.00 | Buy | Loop Capital |
| 11/22/2021 | $100.00 → $120.00 | Buy | HC Wainwright & Co. |
SCHEDULE 13G/A - COMPASS Pathways plc (0001816590) (Subject)
10-Q - COMPASS Pathways plc (0001816590) (Filer)
8-K - COMPASS Pathways plc (0001816590) (Filer)
Evercore ISI downgraded COMPASS Pathways from Outperform to In-line and set a new price target of $6.00 from $11.00 previously
Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00
RBC Capital Mkts initiated coverage of COMPASS Pathways with a rating of Outperform and set a new price target of $23.00
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences: 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on December 2, 2025 Piper Sandler 37th Annual Healthcare Conference – New York, NY: Fireside chat at 1:30pm ET on December 3, 2025 A live audio webcast of these events will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pat
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivate
Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026 Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026 Cash position of $185.9 million as of September 30, 2025 Conference call on November 4 at 8 am ET (1 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental hea
4 - COMPASS Pathways plc (0001816590) (Issuer)
3 - COMPASS Pathways plc (0001816590) (Issuer)
4 - COMPASS Pathways plc (0001816590) (Issuer)
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO. Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a
SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)
SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)
SC 13G - COMPASS Pathways plc (0001816590) (Subject)
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/698442687. The webcast will be archived for 30 days. About Compass Pathways Compass Pathw
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is